Boston Scientific Corp. has received federal approval for a new coronary stent technology, the Natick-based company announced.
The company plans to begin marketing the product – called the PROMUS Element Stent – immediately in the U.S. after approval from the U.S. Food and Drug Administration (FDA). The stent is designed to help doctors in treating patients with coronary artery disease by dissolving clots.
Hank Kucheman, the company’s CEO, called the new product an “important milestone” for Boston Scientific. He said it should boost profits in the U.S. and Japan by $200 million in 2012, accounting for up to one-third of its expected operating profit over the next several years.
